Literature DB >> 27722146

Quantitative Analysis of Exosomes From Murine Lung Cancer Cells by Flow Cytometry.

Kyung-Taek Rim1, Soo-Jin Kim1.   

Abstract

In vivo studies regarding biochemical, molecular biological, and histopathological changes in cancer tissues have been widely performed by the administration of carcinogens in rodents. In these established methods, dissection of the animal following sacrifice must be carried out. Exosomes are cell-derived vesicles that are present in all body fluids and these vesicles have specific roles within cells. Thus, much attention is given to the clinical application of exosomes that can possibly be used for prediction and therapy and as biomarkers related to cancer. To develop a new tool for monitoring in vivo genetic alterations, as a result of carcinogenesis, without the need for frequent euthanasia, we performed quantitative measurement of exosomes in Mlg2908 murine lung fibroblasts and LA-4 and KLN 205 murine lung cancer cells using fluorescence-activated cell sorting. We detected an increase in CD63-specific exosomes in LA-4 lung cancer cells. This result is able to be applied to the classification of cancer-specific proteins and miRNA as diagnostic markers.

Entities:  

Keywords:  Analysis; Exosomes; Flow cytometry; Lung; Quantitative

Year:  2016        PMID: 27722146      PMCID: PMC5051594          DOI: 10.15430/JCP.2016.21.3.194

Source DB:  PubMed          Journal:  J Cancer Prev        ISSN: 2288-3649


INTRODUCTION

Tumor growth and metastasis are dependent on a complex interplay between tumor cells and tumor stroma, as well as tumor-tumor interactions. This communication occurs through direct interaction, secreted factors, and microvesicles. The tumor microvesicles like exosomes carry a wide range of cargo, including oncogenic proteins, fragmented DNA, mRNA, and non-coding RNA, each with regulatory functions that can be transferred between different cells. Increasing attention has been focused on the role of exosomes in malignant progression and metastasis. Because the exosomes are cell-derived vesicles displaying various proteins on their membrane surfaces, they are readily available in blood samples where they constitute potential cancer bio-markers.1 Extracellular vesicles (EVs) are small membranous structures with variable sizes (from 30 nm to a few μm) and released from any type of cell into the extracellular space.2 EVs are detectable in body fluids and responsible to several physiological and pathological processes like inflammation and cancer.3 The term “exosome” was coined by Trams et al. in 19814 for “exfoliated membrane vesicles with 5′-nucleotidase activity.” This term originated from the discovery of the secretion of neoplastic cell line-derived exfoliated vesicles (within larger vesicles), which mirrored the 5′-nucleotidase activity of the parent cells5 and rat reticulocytes.6 Following purification by ultracentrifugation, the sedimented microvesicles were found to contain the transferrin receptor in native reticulocytes.7 The exosomes can be taken up by different types of cancer cells; however, the potential functional effects of mast cell exosomes on tumor cells remain unknown.8 EVs are identified as useful tools for cellular communication in various diseases. Their formation and miRNA content have the ability to transfer biological information to other cancer metastasis-related cells.9 miRNAs harvested from body fluids allows for the development of liquid biopsies that miRNAs as circulating biomarkers can be analyzed ex vivo.10 However, it has limitations in the methods for obtaining high yields of pure exosomes from body fluids.11 In the last few years, the scientific community has started to use the term “liquid biopsy”. A liquid biopsy is a liquid biomarker that can be easily isolated from many body fluids (blood, saliva, urine, ascites, and pleural effusion).12,13 In this study, we were interested in circulating tumor cells, circulating tumor DNA, exosomes, with the aim of demonstrating their usefulness and potential application for lung cancer diagnosis and monitoring of treatment responses. To perform exosomal analysis, it is necessary to develop useful methods by which extract and analyze exosomes from target biofluids without damaging the internal contents.14 We attempted to develop new protocols with which to quantify exosomes, and thus detect carcinogenesis in vitro via measurement using fluorescence-activated cell sorting (FACS). FACS detects the fluorescence emitted from flowing samples and can be used to measure a variety of information related to each cell. It can quickly detect the fluid state of cells as they pass through the detection area (sensing point) and measure simultaneously several features of the cells, including size, intracellular composition, and function. In addition, it can separate only a certain cell type.

MATERIALS AND METHODS

1. Cell lines and culture

Murine Mlg 2908 lung fibroblasts and KLN 205 lung squamous cell carcinoma cells were purchased from American Type Culture Collection (Manassas, VA, USA). LA-4 murine lung adenoma cells were obtained from Korean Cell Line Bank (Seoul, Korea). Mlg 2908 and KLN 205 cells were cultured Eagle’s minimum essential medium supplemented with 10% FBS (HyClone Laboratories, South Logan, UT, USA), and LA-4 cells were cultured in Ham’s F12K medium (Life Technologies, Grand Island, NY, USA). For exosome isolation, exosome free FBS were used.

2. Exosome isolation and purification

Exosomes were isolated and purified with exosome isolation reagent (ExoQuick-TC; System Biosciences, Palo Alto, CA, USA) and exosome purification kit (Exo-FLOW; System Biosciences) according to the manufacturer’s guide (System Biosciences).15 The cultured cells were centrifuged at 3,000 ×g for 15 minutes to discard floating matter. Ten millimeters of supernatant was mixed with 2 mL exosome precipitation solution and incubated overnight with refrigeration. The exosome isolation reagent were added to cell culture media and the mixture was centrifuged at 1,500 ×g for 30 minutes to produce a white pellet of exosomes, followed by further centrifugation at 1,500 ×g for 5 minutes to remove the residual exosome isolation reagent. The exosome pellet was subsequently dissolved in 500 μL buffer.

3. Preparation of magnetic beads and antibody immobilization on the beads

The bead slurry (40 μL) was added to a 1.5-mL tube, incubated on a magnetic stand for 2 minutes, and then washed twice. The tube with bead slurry was removed from the magnetic stand and 10 μL biotinylated capture antibody (CD9 and CD63) was added. After mixing, the tube was incubated on ice for 2 hours with gentle mixing by flicking every 30 minutes. Two hundread micrometers of wash buffer was added and gently flicked to mix. Following sample incubation on the magnetic stand for 2 minutes, the supernatant was discarded gently so as not to scatter the pellet. After removal of the sample from the magnetic stand, 500 μL wash buffer was added and overturned several times. The sample was then washed 3 times in place on the magnetic stand, followed by the final addition of 400 μL wash buffer to the capture antibody-beads.

4. Exosome capture

The separated exosomes were added to bead samples to a final total volume of 500 μL and placed on a rotating shelf at 4°C overnight to capture. The tube was placed on a magnetic stand for 2 minutes and the supernatant was discarded gently so as not to scatter the pellet. After removal of the sample from the magnetic stand, 500 μL wash buffer was added and the tube was gently flicked 2 to 3 times to mix. The samples were placed back on the magnetic stand and washed twice.

5. Exosome staining

Two-hundred forty micrometers of exosome stain buffer and 10 μL Exo-fluorescein isothiocyanate (FITC) exosome staining solution were added to the beads and incubated on ice for 2 hours with gently flicking every 30 minutes to mix. After the sample incubated in magnetic stand for 2 minutes, the supernatant was discarded gently so as not to scatter the pellet. After removal of the sample from the magnetic stand, 500 μL wash buffer was added and gently flicked to mix. The sample was washed 3 times in place on the magnetic stand, followed by the addition of 300 μL wash buffer for FACS analysis, without vortexing.

6. Fluorescence-activated cell sorting analysis

The analyses were performed with FACS Canto II and FACS Diva software (ver. 8.0; BD Biosciences, Franklin Lakes, NJ, USA). The analytical conditions were: forward-scattered light (FSC), 500 nm; scattered light (SSC), 300 nm; and FITC, 420 nm; and more than 5,000 cells were counted.

RESULTS

1. Exosome quantification using fluorescence-activated cell sorting

Normal or cancer cell lines used in the present study are shown in Table 1. Counting the number of each vesicle made it possible to elucidate the proportion of certain vesicles among the total vesicles, and thus the amount of cells that we needed to obtain. Unusually, there were more exosomes secreted in normal cells (Mlg 2908) compared with two cancer cell lines. According to the average FITC-A, 1,670 exosomes were secreted in normal cells (Mlg 2908) compared with the two cancer cell lines (852 in KLN 205 and 1,046 in LA-4) in the case of CD9 antibody binding. With CD63 antibody binding, 1,784 exosomes were secreted in normal cells compared with the two cancer cell lines (845 in KLN 205 and 1,084 in LA-4) (Table 2). FITC indicted the increased exosome-specificity with CD63 in both Mlg 2908 and LA-4 cells with comparison of SSC and FSC (Fig. 1). SSC represents the degree of particle scattering in the cell, which is the complexicity of the cytosol. FSC represents the degree of scattering by the outside of the cell (size), and FITC represents the fluorescence signal relating to either CD9 or CD63 binding to detect a certain vesicle marker.
Table 1

Cell lines used in the present study

VariableName

Mlg 2908LA-4KLN 205
Mouse strainddYA/HeDBA/2
TissueLungLungLung
DiseaseNormalAdenoma (urethane induced)Squamous cell carcinoma
MorphologyaFibroblastEpithelial
Growth propertiesAdherentAdherentAdherent
Cytogenetic analysisModal number = 64; range = 51 to 76Unstable karyotype, range = 38 to 256-

Scale bar = 100 μm.

Table 2

Exosome quantification by FACS

Sample#Events (n)Parent (%)FITC-A mean (n)
Negative control8,23715.2611
CD9 Ab
 F-12K4,98925.4708
 MEM5,02920.0753
 Mlg 29085,07212.61,670
 KLN 2055,01620.5852
 LA-45,00024.61,046
CD63 Ab
 F-12K5,00016.2684
 MEM5,00017.5705
 Mlg 29085,00017.91,784
 KLN 2055,00023.3845
 LA-44,81310.41,084

The analyses were performed with a fluorescence-activated cell sorting (FACS) Canto II and FACSDiva ver. 8.0. The analytical conditions were: FSC, forward-scattered light (500 nm); SSC, scattered light (300 nm); FITC, fluorescein isothiocyanate (420 nm); and we attempted to count more than 5,000 cells. FITC represents the fluorescence signal relating to either CD9 or CD63 binding to detect a certain vesicle marker.

Figure 1

Two-dimensional plots of the exosome fluorescence-activated cell sorting analysis. Exosomes were isolated and purified from murine Mlg 2908 lung fibroblasts, KLN 205 lung squamous cell carcinoma cells, and LA-4 murine lung adenoma cells with (A) CD9 antibody and (B) CD63 antibody. Purifed exosomes were analyzed using fluorescence-activated cell sorting (FACS). SSC, scattered light; FSC, forward-scattered light; FITC, fluorescein isothiocyanate.

DISCUSSION

Since lung cancer is the main human malignancy and causes poor survival in patients with late diagnosis and resistance to classic chemotherapy, it is necessary to identify novel biomarkers for early detection. microRNAs (miRNAs) are considered to show the most remarkable specificity in body fluids. Interestingly, lung cancer patients have revealed high levels of miRNAs in tumor-specific exosomes, and some of these miRNAs are selectively detected in cultured lung cancer cells.16 It is confirmed that tumor cells secrete miRNA-containing exosomes as a powerful cancer biomarker. Although all cell types may contribute to microvesicle shedding, their specific contributions to tumor progression have not established yet.17 Thus, quantification of miRNA in EVs is also an exciting topic in cancer research due to the fact that the amount of extracellular miRNA appears to be upregulated in the plasma of patients bearing tumors.18 There is a growing interest in techniques that allow an absolute quantification of miRNAs, which could be useful for early diagnosis. Recently, digital PCR, mainly based on droplet generation, has emerged as an affordable technology for the precise and absolute quantification of nucleic acids.19 In this study, we analyzed exosome quantification in vitro using FACS in order to replace the existing mouse culling method for the identification of cancer in vivo. It has the potential to be extended into in vivo studies with samples of many bodily fluids (blood, saliva, urine, ascites, and pleural effusion). Although flow cytometry is a powerful method and is widely used for high-throughput quantitative and qualitative analysis of cells, its straightforward applicability to particular exosomes is hampered by several challenges due to small size of these vesicles (exosomes: ~80–200 nm and microvesicles: ~200–1,000 nm) and its poly-dispersity and low refractive index. We performed quantification and characterization of exosomes isolated from cell culture media using a flow cytometer especially designed for small particles. Moreover, our protocol is compatible with antibody labeling using fluorescence-conjugated primary antibodies. Our methodology presents the possibility of routine quantification and characterization of exosomes from various sources. Currently, to facilitate flow cytometry analyses, exosomes are often bound to beads that provide a larger surface area and more scattered light. This detection is largely dependent on the abundance and availability of antigens on the exosomes, which are recognized by the antibody coupled to the beads, reflecting both pros and cons associated with the high specificity of antibodies.20 Exosomal proteins have various functional groups, like CD9, CD63, CD81, heat shock proteins, membrane transporters, and lipid-bound proteins. Tetraspanins are common exosome specific markers and include CD9, CD63, and CD81. Especially, the CD63+ exosomes were increased in patients with melanoma21 and other cancers.22 In the present study, we firstly investigated the tetraspanin family of proteins, CD63 and CD9, as useful markers of exosomes derived from normal and two lung cancer cell lines. From the aspect of cancer diagnosis, circulating exosomes are ideal resources of biomarkers since they carry molecular features of tumor cells. We constructed anti-CD9 and anti-CD63 antibodies that allowed automated rapid and reproducible exosome extraction from cultured cells. Our simple device can promote not only biomarker discovery but also other researches concerning exosomes. Exosomes are secreted by cells in both normal and pathological conditions and contain various membrane and cytosolic proteins. Thus, exosomal proteins can be potentially used for clinical diagnostics.23 Cancer cell-derived EVs have essential roles in tumor progression and microenvironment. Noncancerous cell-derived EVs demonstrate protective functions against damage and repair for maintenance of homeostasis.24 In addition, exosomes derived from fibroblasts have been shown to play a role in the migration of breast cancer cells25 and are protumorigenic with respect to the transfer of mRNA and proangiogenic proteins, contributing to the horizontal transfer of oncogenes such as EGFRvIII.26 A myriad of biological processes in the target cells are affected by exosomes, which induce proliferation and have the potential to convert normal cells into tumor cells. This study was conducted to determine the involvement of exosomes in cancer by the quantitative measurement of one normal (Mlg 2908) and two lung cancer (LA-4 and KLN 205) cell lines. As a notable result, more exosomes were secreted in normal fibroblast (Mlg 2908) cells compared with the two cancer cell lines, according to average FITC-A. The growth of tumors depends upon the balance between proliferation and cell death processes, which are regulated by multiple molecular mechanisms. Since the type of normal cells we used were lung fibroblasts, this is thought to be the reason why they secrete more exosomes compared with cancer cells. Therefore, studies may be necessary to further quantify the exosome secretion by culturing normal cells, fibroblasts, and cancer cells simultaneously. New protocols for isolation do not distinguish the exosomes from ectosomes since the physical properties have not yet been fully characterized and specific markers are still insufficient. According to the average FITC-A, 1,670 exosomes were secreted in normal (Mlg 2908) cells compared with the two cancer cell lines (852 in KLN 205 and 1,046 in LA-4) in the case of CD9 antibody binding. With CD63 antibody binding, 1,784 exosomes were secreted in normal cells compared with the two cancer cell lines (845 and 1,084, respectively), indicating the detection of the increased exosomes with CD63 specificity in Mlg 2908 normal fibroblasts and LA-4 lung cancer cells with both CD9 and CD63 antibody binding, compared with SSC and FSC. The significance and clinical value of exosomes remain still unknown, but current technical challenges have promoted in the rapid isolation and analysis of them. Although the detailed mechanism of resistance remains unclear, inhibition of exosome secretion may present a novel strategy for lung cancer treatment in the future.27 Since the isolation of circulating exosomes is a minimally invasive procedure, this technique presents possibilities for novel diagnostic applications. Our results may contribute the classification of cancer-specific proteins and miRNA as diagnostic markers.
  26 in total

1.  Differential fates of biomolecules delivered to target cells via extracellular vesicles.

Authors:  Masamitsu Kanada; Michael H Bachmann; Jonathan W Hardy; Daniel Omar Frimannson; Laura Bronsart; Andrew Wang; Matthew D Sylvester; Tobi L Schmidt; Roger L Kaspar; Manish J Butte; A C Matin; Christopher H Contag
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

2.  Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes).

Authors:  R M Johnstone; M Adam; J R Hammond; L Orr; C Turbide
Journal:  J Biol Chem       Date:  1987-07-05       Impact factor: 5.157

Review 3.  Extracellular vesicles in lung microenvironment and pathogenesis.

Authors:  Yu Fujita; Nobuyoshi Kosaka; Jun Araya; Kazuyoshi Kuwano; Takahiro Ochiya
Journal:  Trends Mol Med       Date:  2015-07-28       Impact factor: 11.951

4.  Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration.

Authors:  Valbona Luga; Liang Zhang; Alicia M Viloria-Petit; Abiodun A Ogunjimi; Mohammad R Inanlou; Elaine Chiu; Marguerite Buchanan; Abdel Nasser Hosein; Mark Basik; Jeffrey L Wrana
Journal:  Cell       Date:  2012-12-21       Impact factor: 41.582

5.  Comparative marker analysis of extracellular vesicles in different human cancer types.

Authors:  Yusuke Yoshioka; Yuki Konishi; Nobuyoshi Kosaka; Takeshi Katsuda; Takashi Kato; Takahiro Ochiya
Journal:  J Extracell Vesicles       Date:  2013-06-18

Review 6.  The impact of extracellular vesicle-encapsulated circulating microRNAs in lung cancer research.

Authors:  Yu Fujita; Kazuyoshi Kuwano; Takahiro Ochiya; Fumitaka Takeshita
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

7.  Mast cell exosomes promote lung adenocarcinoma cell proliferation - role of KIT-stem cell factor signaling.

Authors:  Hui Xiao; Cecilia Lässer; Ganesh Vilas Shelke; Juan Wang; Madeleine Rådinger; Taral Rameshchand Lunavat; Carina Malmhäll; Li Hui Lin; Jia Li; Li Li; Jan Lötvall
Journal:  Cell Commun Signal       Date:  2014-10-14       Impact factor: 5.712

8.  High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients.

Authors:  Mariantonia Logozzi; Angelo De Milito; Luana Lugini; Martina Borghi; Luana Calabrò; Massimo Spada; Maurizio Perdicchio; Maria Lucia Marino; Cristina Federici; Elisabetta Iessi; Daria Brambilla; Giulietta Venturi; Francesco Lozupone; Mario Santinami; Veronica Huber; Michele Maio; Licia Rivoltini; Stefano Fais
Journal:  PLoS One       Date:  2009-04-17       Impact factor: 3.240

9.  Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma.

Authors:  Vasily N Aushev; Irina B Zborovskaya; Konstantin K Laktionov; Nicolas Girard; Marie-Pierre Cros; Zdenko Herceg; Vladimir Krutovskikh
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

10.  Novel method to detect microRNAs using chip-based QuantStudio 3D digital PCR.

Authors:  Davide Conte; Carla Verri; Cristina Borzi; Paola Suatoni; Ugo Pastorino; Gabriella Sozzi; Orazio Fortunato
Journal:  BMC Genomics       Date:  2015-10-23       Impact factor: 3.969

View more
  10 in total

Review 1.  Therapeutically harnessing extracellular vesicles.

Authors:  Lesley Cheng; Andrew F Hill
Journal:  Nat Rev Drug Discov       Date:  2022-03-02       Impact factor: 84.694

Review 2.  A perspective on the isolation and characterization of extracellular vesicles from different biofluids.

Authors:  Reshma Bano; Farhan Ahmad; Mohd Mohsin
Journal:  RSC Adv       Date:  2021-06-01       Impact factor: 4.036

3.  Cartilage Repair by Mesenchymal Stem Cell-Derived Exosomes: Preclinical and Clinical Trial Update and Perspectives.

Authors:  Shahrbano Jahangir; Mojtaba Khozaei Ravari; Leila Taghiyar; Mohammad Amin Shamekhi; Mohamadreza Baghaban Eslaminejad
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Advances of exosome isolation techniques in lung cancer.

Authors:  Elham O Mahgoub; Ehsan Razmara; Amirreza Bitaraf; Fahimeh-Sadat Norouzi; Maryam Montazeri; Roudabeh Behzadi-Andouhjerdi; Mojtaba Falahati; Ke Cheng; Yousif Haik; Anwarul Hasan; Sadegh Babashah
Journal:  Mol Biol Rep       Date:  2020-08-12       Impact factor: 2.316

5.  Complexity and ultrastructure of infectious extracellular vesicles from cells infected by non-enveloped virus.

Authors:  Jie E Yang; Evan D Rossignol; Deborah Chang; Joseph Zaia; Isaac Forrester; Kiran Raja; Holly Winbigler; Daniela Nicastro; William T Jackson; Esther Bullitt
Journal:  Sci Rep       Date:  2020-05-14       Impact factor: 4.379

Review 6.  Elucidating Methods for Isolation and Quantification of Exosomes: A Review.

Authors:  Talitha Keren Kurian; Soumyabrata Banik; Dharshini Gopal; Shweta Chakrabarti; Nirmal Mazumder
Journal:  Mol Biotechnol       Date:  2021-01-25       Impact factor: 2.695

Review 7.  The application of mesenchymal stromal cells (MSCs) and their derivative exosome in skin wound healing: a comprehensive review.

Authors:  Donghui Bian; Yan Wu; Guodong Song; Ramyar Azizi; Amir Zamani
Journal:  Stem Cell Res Ther       Date:  2022-01-24       Impact factor: 6.832

Review 8.  The Utility of Exosomes in Diagnosis and Therapy of Diabetes Mellitus and Associated Complications.

Authors:  Yaoxiang Sun; Qing Tao; Xueqin Wu; Ling Zhang; Qi Liu; Lei Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-26       Impact factor: 5.555

Review 9.  Perspectives of Microscopy Methods for Morphology Characterisation of Extracellular Vesicles from Human Biofluids.

Authors:  Mladenka Malenica; Marija Vukomanović; Mario Kurtjak; Valentina Masciotti; Simone Dal Zilio; Silvio Greco; Marco Lazzarino; Vedrana Krušić; Marko Perčić; Ivana Jelovica Badovinac; Karmen Wechtersbach; Ivona Vidović; Vanja Baričević; Srećko Valić; Pero Lučin; Nika Kojc; Kristina Grabušić
Journal:  Biomedicines       Date:  2021-05-26

Review 10.  Application of exosomes as liquid biopsy in clinical diagnosis.

Authors:  Biting Zhou; Kailun Xu; Xi Zheng; Ting Chen; Jian Wang; Yongmao Song; Yingkuan Shao; Shu Zheng
Journal:  Signal Transduct Target Ther       Date:  2020-08-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.